Epigenomics AG to Provide an Update on the Septin9 Program During a Corporate Workshop on Colorectal Cancer Screening at the Association of Molecular Pathology (AMP) 2012 Annual Meeting
Published: Oct 22, 2012
The workshop will include a presentation of the results from the pivotal trial with Epigenomics’ colorectal cancer blood test, Epi proColon®, for US pre-market approval, as well as discussions on the individual experiences and perspectives of various groups using the Septin9 biomarker. Presentations will be made by:
Nicholas Potter, Ph.D., FACMG, Chief Scientific Officer and Director of Molecular Diagnostics at Molecular Pathology Laboratory Network, Inc., Maryville, TN
“Septin9 in the Molecular Diagnostics Setting: Results of the Epigenomics Pivotal Trial”
Frederic Waldman, MD Ph.D., Medical Director, Cancer Diagnostics, Quest Diagnostics Nichols Institute, San Juan Capistrano CA
"ColoVantage®, Methylated Septin9: Quest Diagnostics' Experience with its Laboratory- Developed Blood Test for the Colorectal Cancer Genetic Marker After Tens of Thousands of Tests Performed”
Karen Heichman, Ph.D., Adjunct Associate Professor of Pathology at the University of Utah School of Medicine and VP Oncology Technology Development and Licensing of ARUP Laboratories, Inc., Salt Lake City, UT
“ARUP’s Experience with the SEPT9 Blood-based Colorectal Cancer Test”
Professor Dr. Béla Molnár, MD Ph.D., Department of Internal Medicine of Semmelweis University in Budapest, Hungary
“Update on Septin9 Research”
Karen Heichman, Ph.D., Adjunct Associate Professor of Pathology at the University of Utah School of Medicine and VP Oncology Technology Development and Licensing of ARUP said: “ARUP continues to see steady volumes of our Septin9 colorectal cancer test. Based on our collaborative research demonstrating strong patient preference for blood-based testing, it is clear that as physicians and patients become informed, molecular tests such as Septin9 will play an increasing role in patient care."
“We are extremely pleased to have this year’s lineup of speakers and contributors at our workshop,” said Noel Doheny, CEO of Epigenomics’ US Subsidiary. “AMP represents an important opportunity to inform the medical community of the work that we and our partners are doing using Septin9 testing.”
Dr. Thomas Taapken, CEO/CFO of Epigenomics AG remarked that “Epigenomics is highly anticipating the results of its Septin9 biomarker-based test, Epi proColon®, compared directly to the fecal immunochemical test (FIT). The results of the comparison study will be included in the pre-market application for the use of Epi proColon® as a colorectal cancer screening test to be submitted to FDA later this year.”
The workshop is designed to update the AMP laboratory community about the growing opportunity for laboratories to help improve participation in colorectal cancer testing. The increasing availability of blood-based molecular diagnostic method allows patients more flexible choices for their routine health care. The addition of these types of assays provides an innovative role for molecular laboratories and builds on their historic molecular testing expertise.
Contact Epigenomics AG
Manager IR | PR
Tel +49 (0) 30 24345 368
Epigenomics (www.epigenomics.com) is a molecular diagnostics company developing and commercializing a pipeline of proprietary products for cancer. The Company’s products enable doctors to diagnose cancer earlier and more accurately, leading to improved outcomes for patients. Epigenomics’ lead product, Epi proColon®, is a blood-based test for the early detection of colorectal cancer, which is currently marketed in Europe and is in development for the U.S.A. The Company’s technology and products have been validated through multiple partnerships with leading global diagnostic companies including Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an international company with operations in Europe and the U.S.A.
Epigenomics legal disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
The information contained in this communication does not constitute nor imply an offer to sell or transfer any product, and no product based on this technology is currently available for sale by Epigenomics in the United States or Canada. The analytical and clinical performance characteristics of any Epigenomics product based on this technology which may be sold at some future time in the U.S. have not been established.